Apogee Therapeutics (APGE) Director Lisa Bollinger Sells Shares

What Happened
Lisa Bollinger, a director of Apogee Therapeutics (APGE), disposed of a total of 48,780 option-equivalent shares on 2026-09-03 in a transaction marked as "Disposition to the issuer (D)." The filing lists four separate dispositions: 14,461; 7,657; 18,550; and 8,112 option-derived shares. No per-share sale price is reported on the Form 4 because these were cashed out under the merger agreement rather than sold on the open market.

Key Details

• Transaction date: 2026-09-03 (reported on the same date). Transaction code: D (Disposition to issuer).
• Shares/options disposed: 14,461 + 7,657 + 18,550 + 8,112 = 48,780 total. Reported price: N/A on the form.
• Footnotes: F1 states these options were vested as of the Merger date or became fully vested in connection with the Merger. F2 explains each option was exchanged per the Agreement and Plan of Merger for a cash payment equal to the excess of the merger consideration of $135.11 over the option's exercise price.
• Ownership after transaction: not specified in the provided filing.
• Filing timeliness: the report lists the same transaction and filing date (2026-09-03), indicating a timely filing.

Context
These were derivative/option dispositions settled in connection with Apogee’s merger (not open-market sales). The cash received by the option holder equals $135.11 (merger consideration) minus each option’s exercise price, per the merger agreement. Such merger cash-outs are routine outcomes of acquisition deals and do not directly signal the insider's independent view of the company's future performance.